araag2/HINT huggingface dataset:
Clinical trial NCT00408772 (phase 2, status: withdrawn)
Conditions: colorectal cancer, metastatic cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: capecitabine, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    lack of accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed colorectal adenocarcinoma metastatic to the liver

               -  Unresectable liver metastases

          -  Measurable disease

          -  No evidence of extrahepatic metastases

          -  No CNS metastases

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  Absolute neutrophil count > 1,500/mm^3

          -  Platelet count > 100,000/mm^3

          -  Creatinine ≤ 1.5 times upper limit of normal (ULN) OR creatinine clearance ≥ 45 mL/min

          -  Urinary protein < 2+ by dipstick OR < 2 g by 24-hour urine collection

          -  Bilirubin < 2 times ULN

          -  SGOT and SGPT < 2 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 18 months after
             completion of study therapy

          -  Able to take oral medications (e.g., no dysphagia or malabsorption symptoms)

          -  No other prior malignancy unless in complete remission and off therapy for ≥ 5 years

          -  No known allergy to the study drugs

          -  No peripheral neuropathy > grade 1

          -  No uncontrolled infection

          -  No uncontrolled hypertension

          -  No active bleeding or hemoptysis

          -  No other serious concurrent illness within the past 12 months, including any of the
             following:

               -  Nonstable coronary artery disease

               -  Myocardial infarction

               -  Transient ischemic attack

               -  Cardiovascular accident

        PRIOR CONCURRENT THERAPY:

          -  Recovered from prior therapy

          -  At least 28 days since prior major surgery

          -  Prior therapy for advanced disease allowed

               -  No prior oxaliplatin-based therapy

          -  Concurrent maintenance and palliative treatment during study chemotherapy allowed
             (e.g., nutritional or transfusional support or pain control)

          -  No concurrent corticosteroids except when used under the following circumstances:

               -  As oxaliplatin premedication

               -  Anti-5-HT_3 as antiemetic

          -  No concurrent cold cap or iced mouth rinses

          -  No other concurrent chemotherapy

          -  No placement of hepatic artery port for regional chemotherapy
Clinical trial NCT00106405 (phase 2, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: memantine hcl
SMILES: CC12CC3CC(C)(C1)CC(N)(C3)C2
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have a documented clinical diagnosis of bipolar I disorder and must be
             currently experiencing a manic or mixed episode.

          -  Patients must be voluntarily hospitalized with a primary diagnosis of mania.

        Exclusion Criteria:

          -  Rapid cycling bipolar disorder.

          -  Suicidal risk.

          -  First manic episode.

          -  ECT, clozapine or a depot neuroleptic in the past 3 months.

          -  Substance dependence.

          -  Known HIV infection.

          -  Co-morbid serious, uncontrolled systemic illness.
Clinical trial NCT00003910 (phase 2, status: terminated)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: cyclophosphamide, methotrexate, prednisone
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Eligibility criteria:

        Inclusion:

          -  Phenotypic studies from peripheral blood showing CD3+, CD57+ cells greater than
             400/mm3 or CD8+ cells greater than 650/mm3 within eight weeks prior to registration

          -  Evidence for clonal T-cell receptor gene rearrangement within one year prior to
             registration

          -  At least one of the following: Severe neutropenia less than 500/mm3, neutropenia
             associated with recurrent infections, symptomatic anemia, or transfusion-dependent
             anemia

          -  Bilirubin ≤ 2.0 mg/dl, SGOT(AST) ≤ 1.5 times normal, and Creatinine ≤ 2.0 mg/dl within
             4 weeks prior to registration

          -  ECOG performance status of 0-2

          -  At least 18 years of age

          -  Written informed consent

        Exclusion:

          -  Prior therapy with oral MTX or oral Cy

          -  Previous or concurrent malignancies except inactive non-melanoma skin cancer, in situ
             carcinoma of the cervix, or other cancer if the patient has been disease free for over
             5 years

          -  Pregnant or breast-feeding for female patients

          -  Serious medical illness, other than that treated by the study, which would limit
             survival to less than 2 years, or psychiatric condition which would prevent informed
             consent

        Note: to be eligible for step 2 of this study, patients were required to have no response
        after at least 4 months of methotrexate treatment.
Clinical trial NCT00386087 (phase 2, status: completed)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: enzastaurin hydrochloride
SMILES: CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of metastatic breast cancer or recurrent breast cancer where
             surgery can not be done for curative intent

          -  Have received prior therapy with an anthracycline (class of drugs) and a taxane (class
             of drugs).

          -  Tumors must not be positive for HER2, but if positive, the treatment plan should not
             include further treatment with the drug Herceptin.

          -  Disease that can be definitely measured on Cat Scans or other radiological tests.

          -  May have received high dose chemotherapy for autologous stem cell support greater than
             or equal to 6 months of starting this study.

        Exclusion Criteria:

          -  More than 2 chemotherapy regimens for metastatic or locally recurrent disease.

          -  Have brain cancer from breast cancer

          -  Pregnant or breastfeeding

          -  Have an inability to swallow tablets

          -  Within 6 months have had a serious heart condition
Clinical trial NCT01140542 (phase 2, status: completed)
Conditions: diabetes mellitus type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: roflumilast
SMILES: FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  given written informed consent

          -  patients with diagnosis of type 2 diabetes according to American Diabetes Association
             (ADA) criteria and inadequately controlled on diet and exercise alone

          -  HbA1c at baseline: ≥7.5 percent to 8.5 percent (up to 9 percent in Mexico, Ukraine and
             Romania)

          -  BMI between ≥26 and ≤35 kg/m2

          -  willingness of patient to check his/her blood glucose with equipment provided by the
             sponsor during the treatment phase in case of hypo-/hyperglycemia episodes

          -  willingness to adhere to the physician's advise to comply with diet and exercise

        Main Exclusion Criteria:

          -  patients diagnosed with type 1 diabetes or diabetes secondary to pancreatitis or
             resection of pancreas

          -  patients diagnosed with hemoglobinopathies, hemolytic anemia or other diseases which
             interfere with HbA1c measurement

          -  non-euthyroid patients or patients with a non-controlled hypo- or hyperthyroidism

          -  reported gain or loss of more than 5 percent of body weight within the last 2 months
             prior to V0

          -  treatment with any diabetes medication prior to V0

          -  treatment with any weight-loss medication within 3 months prior to V0

          -  treatment with any not allowed medication or nutrition additives

          -  clinically relevant abnormal laboratory values suggesting an unknown disease and
             requiring further clinical evaluation (as assessed by the investigator)

          -  clinically significant cardiac abnormalities (diagnosed clinically, or by X-ray/ECG)
             that were not related to type 2 diabetes mellitus and that required further evaluation

          -  participation in a clinical study with study medication for weight loss or type 2
             diabetes

        Patients were randomized after 2 weeks of the baseline period, if the following criteria
        were fulfilled:

          -  judged to be clinically stable

          -  tablet compliance ≥80 percent and ≤125 percent

          -  HbA1c in the range of 7.5 percent to 8.5 percent (up to 9 percent in Mexico, Ukraine
             and Romania) tested at V0 by the central laboratory
Clinical trial NCT00231140 (phase 2, status: terminated)
Conditions: amyotrophic lateral sclerosis (als)
ICD codes: G12.21
Drugs: thalidomide (drug)
SMILES: O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  patients aged 25 and 80 years

          -  female patients who are either postmenopausal for at least 24 month or who are willing
             and able to practice the methods of contraception following the Pharmion-Risk
             Managment Program (PRMP)

          -  Male patients who are willing and able to practice the methods of contraception along
             with their female partners of childbearing potential following the PRMP

          -  Clinical diagnosis of probable and definite ALS

          -  Sporadic or familial ALS

          -  Onset of pareses for no more than 4 years

          -  Vital capacity equal to or more than 65% of the predicted value

          -  Treatment with riluzole 100mg/day

          -  Patients who are willing to give informed consent

        Exclusion Criteria:

          -  pregnancy or breast feeding

          -  female patients who are unwilling or unable to practice the methods of contraception
             following the Pharmion-Risk Managment Program (PRMP)

          -  Male patients who are willing and able to practice the methods of contraception along
             with their female partners of childbearing potential following the PRMP

          -  Patients unlikely to comply with the PRMP and other study requirements

          -  Patients with significant sensory abnormalities, dementia, uncompensated medical
             illnesses and psychiatric disorders

          -  Laboratory abnormalities consistent with clinically significant cardiovascular,
             respiratory, haematological, metabolic, hepatic and renal disease

          -  Infectious disease including HIV, hepatitis B and C

          -  monoclonal gammopathy of unknown significance (MGUS)

          -  History of substance abuse within the past year

          -  History of recurrent thrombosis

          -  Continuous non-invasive ventilation (ventilation-free interval equal to or less than 2
             hours daily)

          -  Tracheotomy and invasive ventilation

          -  Treatment with investigational drug within 3 months prior to screening

          -  patients with clinically signifikant sensory polyneuropathy (inflammatory neuropathy
             cause and treatment sensory sum score - ISS ≥ 2)

          -  patients with sleep disorder (Epworth Sleeping Scale-ESS ≥ 10)
Clinical trial NCT00193479 (phase 2, status: completed)
Conditions: non-hodgkins lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: cyclophosphamide, mitoxantrone, vincristine, prednisone, rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

        To be included in this study, you must meet the following criteria:

          -  Histologically documented large B-cell, CD20-positive non-Hodgkin's lymphoma

          -  No previous treatment

          -  Clinical stage II, III, or IV by the Ann Arbor Staging Criteria

          -  Age > 70 years

          -  ECOG performance status 0, 1, or 2

          -  Adequate bone marrow, liver and kidney function

          -  Must give written informed consent prior to entering this trial

        Exclusion Criteria:

        You cannot participate in this study if any of the following apply to you:

          -  Age < 18 years

          -  Central nervous system involvement with lymphoma

          -  Coexistent active malignancies treated within five years

          -  Active infection precluding the use of combination chemotherapy

          -  HIV infection

          -  Pregnant or lactating

        Please note: There are additional inclusion/exclusion criteria. The study center will
        determine if you meet all of the criteria. If you do not qualify for the trial, study
        personnel will explain the reasons. If you do qualify, study personnel will explain the
        trial in detail and answer any questions you may have.
Clinical trial NCT00476827 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: bevacizumab, docetaxel, cpt-11, paclitaxel, vinorelbine tartrate, gemcitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Female, 18+, with evaluable metastatic breast cancer and stable brain metastases

          -  Must have received definitive radiotherapy

          -  No evidence, or history of, central nervous system hemorrhage

          -  Adequate organ and hematological function

        Exclusion Criteria:

          -  Active infection, non-healing wound, or history of any bleeding diathesis or
             coagulopathy

          -  Uncontrolled hypertension, congestive heart failure, peripheral vascular disease
Clinical trial NCT00730262 (phase 2, status: terminated)
Conditions: glioblastoma multiforme
ICD codes: L51.0, L51.8, L51.9
Drugs: tln-4601
SMILES: CC(C)=CCC\C(C)=C\CC\C(C)=C\CN1C2=CC(O)=CC(O)=C2NC2=C(C=CC=C2O)C1=O
Reason stopped: 
    lack of efficacy
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed Glioblastoma Multiforme (GBM)

          -  Prior treatment with radiation and one first line systemic therapy (including
             temozolomide or other chemotherapy, immunotherapy, targeted therapy or combination
             therapies), followed by measurable and unequivocal evidence of tumor progression or
             recurrence

          -  Age ≥ 18 years

          -  ECOG ≤ 2

          -  Normal organ and marrow function as defined below:

               -  leukocytes ≥3 x 109/L

               -  absolute neutrophil count ≥1.5 x 109/L

               -  platelets ≥100 x 109/L

               -  hemoglobin ≥90 g/L

               -  total bilirubin ≤2.5 X institutional upper limit of normal

               -  AST(SGOT)/ALT(SGPT) ≤2.5 X institutional upper limit of normal

               -  creatinine ≤1.0 X institutional upper limit of normal

        Exclusion Criteria:

          -  Patients with a life expectancy < 12 weeks

          -  Patients with a documented history of HIV, active hepatitis B or C infections

          -  Female patients who are pregnant or lactating

          -  Patients in whom a proper central line (Portacath-like device) cannot be established

          -  Patients with a known hypersensitivity to farnesylated dibenzodiazepinone or
             polysorbate 80

          -  Patients with uncontrolled hypotension

          -  Patients with concomitant therapy of therapeutic coumadin
Clinical trial NCT00394966 (phase 2, status: completed)
Conditions: nausea, vomiting
ICD codes: R11.0, R11.11, R11.2, R11.10, R11.12, R11.14, R11.11, K91.0, O21.2, O21.8
Drugs: sch 619734 dose 1, sch 619734 dose 2, sch 619734 dose 3, sch 619734 dose 4, placebo
SMILES: C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C1=CC=CC=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C1=CC=CC=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C1=CC=CC=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C1=CC=CC=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject is 18 years of age or older.

          -  Subject has never been treated with cisplatin and is to receive first course of
             cisplatin-based chemotherapy (>=70 mg/m^2).

          -  Subject has a Karnofsky performance score of >=60.

          -  Subject has a predicted life expectancy of >=3 months.

          -  Subject has adequate bone marrow, kidney, and liver function as evidenced by:

               -  Absolute neutrophil count >=1,500/mm3 and white blood cell count >=3,000/mm3.

               -  Platelet count >=100,000/mm3.

               -  Aspartate aminotransferase (AST) <=2.5 x upper limit of normal (ULN) range.

               -  Alanine aminotransferase (ALT) <=2.5 x ULN.

               -  Bilirubin <=1.5 x ULN, except for subjects with Gilbert's syndrome.

               -  Creatinine <=1.5 x ULN.

          -  Subject is able to read, understand, and complete the questionnaires.

        Exclusion Criteria:

          -  Any current treatment or medical history (eg, subject is mentally incapacitated or has
             a psychiatric disorder) that, in the opinion of the investigator, would confound the
             results of the study or pose any unwarranted risk in administering study drug to the
             subject.

          -  Subject has contraindication to the administration of cisplatin, ondansetron, or
             dexamethasone including, but not limited to, a history of hypersensitivity to the
             drugs or their components, severe renal impairment, severe bone marrow suppression,
             hearing impairment, or systemic fungal infection.

          -  Subject is scheduled to receive any other chemotherapeutic agent with an emetogenicity
             level of 3 or above (Hesketh Scale) from Day -2 through Day 6.

          -  Subject is scheduled to receive any radiation therapy to the abdomen or pelvis within
             5 days prior to and/or during Days 1 through 5 following cisplatin infusion.

          -  Subject has symptomatic primary or metastatic central nervous system (CNS) disease.

          -  Subject has ongoing vomiting caused by any etiology or has a history of anticipatory
             nausea and vomiting.
Clinical trial NCT01568229 (phase 2, status: terminated)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: amg 747, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    toxic epidermal necrolysis
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition,
             Text Revision (DSM-IV-TR) schizophrenia

          -  Total score on the PANSS Marder Negative Symptom Factor Scale (NSFS) ≥ 20

          -  Total score on the PANSS Marder Positive Symptom Factor Scale (PSFS) ≤ 30

          -  Receiving stable antipsychotic therapy for at least 8 weeks prior to screening

          -  Receiving a stable dose of other psychotropic agents for at least 8 weeks prior to
             screening

          -  Subject has had a stable residence or living arrangement for at least 8 weeks prior to
             screening and the residence or living arrangement is not anticipated to change for the
             duration of the study

          -  The subject or subject's legally acceptable representative has provided informed
             consent.

        Exclusion Criteria:

          -  Current schizoaffective or bipolar disorder, panic disorder, obsessive compulsive
             disorder, evidence of mental retardation by history or clinical examination or known
             premorbid IQ ≤ 70

          -  Clinically significant suicidal ideation or suicide attempts, assaultive behavior or
             marked changes in mood within the 8 weeks prior to screening, or currently endorsing
             suicidal ideation in clinical exam

          -  Substance abuse (with the exception of nicotine or caffeine abuse) within the 8 weeks
             prior to screening, or during screening

          -  Substance dependence (with the exception of nicotine or caffeine dependence) within
             the 6 months prior to screening, or during screening

          -  Planning to initiate a smoking cessation therapy or otherwise substantially modify
             nicotine use during the study

          -  Positive urine drug test for substances of abuse (with the exception of positive
             screens for prescribed agents such as benzodiazepines).

          -  Other criteria may apply